BLOG

After Final Medicare LCD from Palmetto GBA, OncoCyte Pursues Private Coverage for NSCLC Stratification Test

Molecular diagnostics developer OncoCyte said it will step up its pursuit of coverage by private insurers for its DetermaRx™ non-small cell lung cancer (NSCLC) test, after receiving a final local coverage determination (LCD) from Palmetto GBA, the Medicare Administrative Contractor for the Centers for Medicare & Medicaid Services (CMS).

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}